BioDlink International Co (HKSE:01875) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01875 BioDlink International Co Ltd HKSE:01875
64 GF Score
Price HK$4.02
GF Value HK$1.47
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is BioDlink International Co Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

HKSE:01875
64GF Score
BioDlink International Co Ltd HKSE:01875
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioDlink International Co (HKSE:01875) Overvalued in 2026?

Based on GuruFocus' analysis, BioDlink International Co stock appears to be overvalued. The current stock price of HK$4.02 is trading 173.5% above its estimated GF Value™ of HK$1.47. GuruFocus considers BioDlink International Co to be Significantly Overvalued.

Key valuation signals for HKSE:01875:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: HK$1.47 vs. price of HK$4.02 (173.5% above fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the HKSE:01875 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioDlink International Co Business Description

Address 120 Changyang Street, Suzhou Industrial Park, Suzhou, CHN, 215024
BioDlink International Co Ltd is an investment holding company. The Company is mainly engaged in research and development (R&D), manufacturing, and marketing of anti-tumor drugs, contract development and manufacturing organization (CDMO), contract manufacturing organization (CMO) business and license-out of self-developed biological drugs. The company has presence in Mainland China, and Others. The company's services includes ADC R&D Service Platform, Chemical based conjugation process development, Developability assessment for drug product, Drug substance analysis, Antibody Manufacturing, Drug product analysis, etc.
64GF Score

Get the complete analysis for HKSE:01875

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$4.02
Price
HK$1.47
GF Value